Perrigo (PRGO) Cash from Financing Activities (2013 - 2026)
Perrigo's (PRGO) quarterly Cash from Financing Activities came in at -$45.3 million in Q1 2026, up 26.7% year-on-year from -$35.8 million in Q1 2025, and up 16.73% on a QoQ basis from -$54.4 million in Q4 2025.
Perrigo (PRGO) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Cash from Financing Activities data on file, last reported at -$45.3 million in Q1 2026.
- On a quarterly basis, Cash from Financing Activities rose 26.7% year-over-year to -$45.3 million in Q1 2026; TTM through Mar 2026 was -$204.0 million, a 66.69% increase from a year earlier, with the FY2025 full-year figure at -$220.5 million, up 63.91% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$45.3 million, up from -$54.4 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for PRGO reached as high as $653.3 million in Q3 2024 and fell as low as -$1.2 billion in Q4 2024.
- Historically, Cash from Financing Activities has averaged -$37.8 million across 5 years, with a median of -$49.8 million in 2024.
- On a YoY basis, Cash from Financing Activities climbed as much as 1608.78% in 2024 and fell as far as 2487.67% in 2024.
- Year by year, Cash from Financing Activities stood at -$42.5 million in 2022, then dropped by 4.94% to -$44.6 million in 2023, then plunged by 2487.67% to -$1.2 billion in 2024, then surged by 95.29% to -$54.4 million in 2025, then advanced by 16.73% to -$45.3 million in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were -$45.3 million in Q1 2026, -$54.4 million in Q4 2025, and -$50.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Perrigo | 1.40 Bn | 1.05 Bn | 325.50 Mn | -45.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | -45.30 Mn |
| Mar 28, 2026 | -45.30 Mn |
| Dec 31, 2025 | -54.40 Mn |
| Dec 31, 2025 | -54.40 Mn |
| Sep 27, 2025 | -50.30 Mn |
| Sep 27, 2025 | -50.30 Mn |
| Jun 28, 2025 | -54.00 Mn |
| Jun 28, 2025 | -54.00 Mn |
| Mar 29, 2025 | -61.80 Mn |
| Mar 29, 2025 | -61.80 Mn |
| Dec 31, 2024 | -1.15 Bn |
| Dec 31, 2024 | -1.15 Bn |
| Sep 28, 2024 | 653.30 Mn |
| Sep 28, 2024 | 653.30 Mn |
| Jun 29, 2024 | -49.80 Mn |
| Jun 29, 2024 | -49.80 Mn |
| Mar 30, 2024 | -60.40 Mn |
| Mar 30, 2024 | -60.40 Mn |
| Dec 31, 2023 | -44.60 Mn |
| Dec 31, 2023 | -44.60 Mn |